{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:43:19Z","timestamp":1790664199508,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jacc.2018.11.033","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T17:40:53Z","timestamp":1549302053000},"page":"602-611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":278,"title":["Heart Failure With Preserved Ejection\u00a0Fraction and Diabetes"],"prefix":"10.1016","volume":"73","author":[{"given":"Kelly","family":"McHugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"DeVore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland A.","family":"Matsouaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde W.","family":"Yancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.11.033_bib1","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.11.033_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.11.033_bib3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/CIRCULATIONAHA.116.025957","article-title":"The diabetic heart failure with preserved ejection fraction phenotype: is it real and is it worth targeting therapeutically?","volume":"135","author":"Lindman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.11.033_bib4","first-page":"619","article-title":"Heart failure with preserved ejection fraction expert panel report: current controversies and implications for clinical trials","volume":"6","author":"Parikh","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2018.11.033_bib5","series-title":"National Diabetes Statistics Report, 2017","year":"2017"},{"key":"10.1016\/j.jacc.2018.11.033_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/pop.2015.0181","article-title":"Diabetes 2030: insights from yesterday, today, and future trends","volume":"20","author":"Rowley","year":"2017","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.jacc.2018.11.033_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","article-title":"Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry","volume":"182","author":"Echouffo-Tcheugui","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2018.11.033_bib8","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.033_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ahj.2014.07.008","article-title":"Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population","volume":"168","author":"Cheng","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2018.11.033_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11897-014-0223-7","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"11","author":"Dhingra","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jacc.2018.11.033_bib11","first-page":"653","article-title":"Sudden death in heart failure with preserved ejection fraction: a competing risks analysis from the TOPCAT trial","volume":"6","author":"Vaduganathan","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2018.11.033_bib12","doi-asserted-by":"crossref","first-page":"e004962","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2018.11.033_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2018.11.033_bib14","first-page":"507","article-title":"Biomarker profiles of acute heart failure patients with a mid-range ejection fraction","volume":"5","author":"Tromp","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2018.11.033_bib15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000450573","article-title":"Clinical application of biomarkers in heart failure with a preserved ejection fraction: a review","volume":"136","author":"Garg","year":"2017","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2018.11.033_bib16","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ehj.2004.01.010","article-title":"Impact of diabetes mellitus on long-term survival in patients with congestive heart failure","volume":"25","author":"De Groote","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.11.033_bib17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.11.033_bib18","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2018.11.033_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjcard.2009.09.041","article-title":"Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus","volume":"105","author":"Aguilar","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2018.11.033_bib20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","volume":"135","author":"Kristensen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.11.033_bib21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","article-title":"Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study","volume":"64","author":"Lindman","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.033_bib22","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ahj.2004.09.015","article-title":"The American Heart Association Get With The Guidelines program","volume":"148 Suppl","author":"Smaha","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2018.11.033_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes","volume":"126","author":"Steinberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.11.033_bib24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.11.033_bib25","first-page":"341583","article-title":"Relevance of sympathetic nervous system activation in obesity and metabolic syndrome","volume":"2015","author":"Thorp","year":"2015","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.jacc.2018.11.033_bib26","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.11.033_bib27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors","volume":"19","author":"Butler","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2018.11.033_bib28","first-page":"136","article-title":"Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure","volume":"3","author":"Dei Cas","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2018.11.033_bib29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/dom.12884","article-title":"Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial","volume":"19","author":"von Scholten","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2018.11.033_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2017.04.001","article-title":"Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice","volume":"261","author":"Jojima","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2018.11.033_bib31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.11.033_bib32","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/dc11-0442","article-title":"Globalization of diabetes","volume":"34","author":"Hu","year":"2011","journal-title":"Diabetes Care"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718393987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718393987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:19:32Z","timestamp":1760015972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109718393987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0735109718393987"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.11.033","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart Failure With Preserved Ejection\u00a0Fraction and Diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.11.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}